Previous article Next article

The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing for a range of off-patent cancer medicines (Aspen)

Today, the European Commission (the Commission) started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings (Aspen) to address the Commission's concerns over excessive pricing for a range of off-patent cancer medicines (see, attached Commission press release). Broadly, Aspen’s proposed commitments are the following: a) Applying a price

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing for a range of off-patent cancer medicines (Aspen), 14 July 2020, e-Competitions Preview, Art. N° 95821

Visites 120

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues